Our findings imply that Nrf2/HO-1 and MBP levels in brain homogenate, blood plasma, and CSF can be used as an earlier stage diagnostic marker to detect major degenerative characteristics of the MS brain. This evidence concerns the gene HMOX1 and myeloid sarcoma.